Radiotherapy of oligometastatic prostate cancer: a systematic review.
ENRT
Metastasis‐directed therapy
Oligometastatic prostate cancer
Radiotherapy
SBRT
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
09 Mar 2021
09 Mar 2021
Historique:
received:
08
02
2021
accepted:
24
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
19
11
2021
Statut:
epublish
Résumé
Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients. A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence. Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients.
METHODS
METHODS
A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence.
FINDINGS
RESULTS
Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of
CONCLUSIONS
CONCLUSIONS
To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.
Identifiants
pubmed: 33750437
doi: 10.1186/s13014-021-01776-8
pii: 10.1186/s13014-021-01776-8
pmc: PMC7941976
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Références
Radiat Oncol. 2018 Sep 21;13(1):185
pubmed: 30241556
J Cancer Res Clin Oncol. 2019 Oct;145(10):2469-2479
pubmed: 31444549
Technol Cancer Res Treat. 2016 Oct;15(5):661-73
pubmed: 26208835
Eur Urol. 2019 Jan;75(1):176-183
pubmed: 30301694
Cancer Med. 2018 Sep;7(9):4379-4386
pubmed: 30073758
Clin Genitourin Cancer. 2015 Aug;13(4):e279-e284
pubmed: 25604915
Cancer Treat Rev. 2019 Feb;73:84-90
pubmed: 30684842
World J Urol. 2019 Aug;37(8):1535-1542
pubmed: 30824985
Eur Urol. 2018 Oct;74(4):455-462
pubmed: 30227924
Clin Genitourin Cancer. 2020 Aug 6;:
pubmed: 32863189
Radiat Oncol. 2018 Mar 2;13(1):37
pubmed: 29499730
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur Urol. 2016 Jan;69(1):9-12
pubmed: 26189689
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94
pubmed: 25975367
Strahlenther Onkol. 2016 Jul;192(7):431-9
pubmed: 27272755
J Natl Cancer Inst. 2005 Jun 1;97(11):798-804
pubmed: 15928300
Am J Clin Oncol. 2018 Oct;41(10):960-962
pubmed: 29315174
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13093
pubmed: 31115124
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
World J Urol. 2017 Jan;35(1):45-49
pubmed: 27233779
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97
pubmed: 21277113
Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782
pubmed: 28462855
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):406-410
pubmed: 29559285
Pulm Med. 2012;2012:541656
pubmed: 22991663
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):387-395
pubmed: 32798608
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Eur Urol Focus. 2019 Nov;5(6):1007-1013
pubmed: 29530632
Br J Radiol. 2020 Apr;93(1108):20190353
pubmed: 31971828
Med Oncol. 2018 Apr 18;35(5):75
pubmed: 29671075
Eur Urol Oncol. 2018 Dec;1(6):531-537
pubmed: 31158100
Radiat Oncol. 2014 Jun 12;9:135
pubmed: 24920079
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2328-2338
pubmed: 32179961
BJU Int. 2019 Nov;124 Suppl 1:19-30
pubmed: 31507035
Eur Urol Oncol. 2019 Sep 23;:
pubmed: 31558422
World J Urol. 2015 Aug;33(8):1197-203
pubmed: 25342516
Clin Transl Oncol. 2018 Apr;20(4):484-490
pubmed: 28795303
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
J Oncol Pract. 2017 Jan;13(1):9-18
pubmed: 28045610
Clin Genitourin Cancer. 2013 Mar;11(1):27-32
pubmed: 23010414
World J Urol. 2019 Dec;37(12):2631-2637
pubmed: 30859273
Acta Oncol. 2013 Nov;52(8):1622-8
pubmed: 23544357
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
BMC Cancer. 2017 May 22;17(1):361
pubmed: 28532400
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Strahlenther Onkol. 2020 Mar;196(3):213-221
pubmed: 31559480
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702
pubmed: 27131082
BMC Cancer. 2020 Apr 29;20(1):362
pubmed: 32349700
World J Clin Oncol. 2019 Feb 24;10(2):38-51
pubmed: 30815370
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
Cancer. 2019 Feb 1;125(3):340-352
pubmed: 30521067
Cancers (Basel). 2020 Aug 13;12(8):
pubmed: 32823690
Radiat Oncol. 2016 Jan 22;11:9
pubmed: 26796633
Br J Cancer. 2017 Jun 6;116(12):1520-1525
pubmed: 28449007
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):143-151
pubmed: 32405735
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
BJU Int. 2017 Mar;119(3):406-413
pubmed: 27104782
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104
pubmed: 30201438
Int J Cancer. 2020 Jan 1;146(1):161-168
pubmed: 31199504
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):40-48
pubmed: 30267117
Strahlenther Onkol. 2018 Apr;194(4):318-324
pubmed: 29181556
Radiat Oncol. 2018 May 11;13(1):90
pubmed: 29751842
Eur Urol. 2019 Dec;76(6):732-739
pubmed: 31331782
World J Urol. 2019 Dec;37(12):2615-2621
pubmed: 31346760
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):948-956
pubmed: 31419509
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20
pubmed: 24072344
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Medicine (Baltimore). 2016 Feb;95(6):e2789
pubmed: 26871838
Eur Urol Focus. 2019 Sep 5;:
pubmed: 31495759
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Strahlenther Onkol. 2020 Nov;196(11):1034-1043
pubmed: 32617620
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1852-1863
pubmed: 32002591
PLoS One. 2020 Oct 21;15(10):e0240892
pubmed: 33085712
Urol Oncol. 2013 May;31(4):455-60
pubmed: 21481619
Curr Oncol Rep. 2019 Mar 27;21(5):43
pubmed: 30919165
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632
pubmed: 28185875
Sci Rep. 2020 Oct 15;10(1):17471
pubmed: 33060732
Radiat Oncol. 2017 Nov 10;12(1):176
pubmed: 29126446
Oncol Res Treat. 2018;41(11):703-705
pubmed: 30317236
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301